A reminder. EMA is going just to issue an opinion to MHRA. There is NO decision from EMA, therefore it is not subject to the Committee schedule.
AXN Rising demand, China's 'tech war' bans leaves this germanium explorer with significant investment potential
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025